Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20916576 | 0.89 | MAPT (0.46) | ALDH1A1NPSR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20916667 | 0.86 | HPGD (0.40) | KMT2AMEN1NPSR1NPC1RAB9A | |
| SCHEMBL20916459 | 0.74 | DPP4 (0.37) | KMT2AMEN1NPSR1NPC1RAB9A | |
| SCHEMBL20916513 | 0.74 | SMN1; SMN2 (0.39) | KMT2AMEN1NPSR1NPC1RAB9A | |
| SCHEMBL7166716 | 0.73 | OXER1 (0.52) | ALDH1A1P2RX4KMT2AMEN1NPSR1 | |
| SCHEMBL7955788 | 0.72 | LMNA (0.44) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL3375069 | 0.72 | TDP1 (0.47) | ALDH1A1P2RX4KMT2AMEN1NPSR1 | |
| SCHEMBL4232805 | 0.72 | TACR3 (0.43) | ALDH1A1P2RX4KMT2AMEN1NPSR1 | |
| SCHEMBL13309267 | 0.71 | NPC1 (0.48) | ALDH1A1P2RX4KMT2AMEN1NPSR1 | |
| SCHEMBL7162130 | 0.71 | L3MBTL1 (0.53) | ALDH1A1P2RX4KMT2AMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | Effector Therapeutics Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | Effector Therapeutics Inc. (US) | 2020-10-06 | — | — | US | disclosed |
| EP-3697777-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | eFFECTOR Therapeutics, Inc. (US) | 2020-08-26 | — | — | EP | disclosed |
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-04-25 | — | — | US | disclosed |
| WO-2019079369-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119256-A1 | BENZIMIDAZOLE-INDOLE INHIBITORS OF MNK1 AND MNK2 | NEK5, MINK1, NIM1K | ALDH1A1 4320/4885P2RX4 2017/4885KMT2A 1437/4885 |
| US-10793551-B2 | Benzimidazole-indole inhibitors of Mnk1 and Mnk2 | NEK5, MINK1, NIM1K | ALDH1A1 4320/4885P2RX4 2017/4885KMT2A 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.